重组带状疱疹疫苗在50岁及以上类风湿关节炎患者中的有效性与安全性:一项匹配队列与自控病例系列研究
该研究在50岁及以上类风湿关节炎患者中评估重组带状疱疹疫苗对带状疱疹及带状疱疹后神经痛的有效性和安全性。匹配队列分析显示,2剂重组带状疱疹疫苗对带状疱疹的调整疫苗有效性为60.7%(95%CI 41.0%-73.8%),对带状疱疹后神经痛的调整疫苗有效性为88.7%(95%CI 12.1%-98.5%)。自控病例系列分析未观察到接种后30天内类风湿关节炎 flare 风险增加(RR 1.02;95%CI 0.75-1.37)。
要点
- 50岁及以上类风湿关节炎患者接种2剂重组带状疱疹疫苗对带状疱疹的调整疫苗有效性为60.7%(95%CI 41.0%-73.8%)。
- 2剂重组带状疱疹疫苗对带状疱疹后神经痛的调整疫苗有效性为88.7%(95%CI 12.1%-98.5%)。
- 2606例接种至少1剂重组带状疱疹疫苗的类风湿关节炎患者中,接种后30天内类风湿关节炎 flare 风险未增加(RR 1.02;95%CI 0.75-1.37)。
核心结论
- 在50岁及以上类风湿关节炎成人中,2剂重组带状疱疹疫苗提供了针对带状疱疹和带状疱疹后神经痛的保护。
- 研究未观察到重组带状疱疹疫苗接种后30天内类风湿关节炎 flare 风险增加。
研究设计与样本
- 疫苗有效性通过回顾性匹配队列分析评估,对象为Kaiser Permanente Southern California中50岁及以上、接种2剂重组带状疱疹疫苗(间隔至少4周)的类风湿关节炎成员,并按最多1:3匹配未接种者。
- 采用分层Cox比例风险回归估计调整风险比和疫苗有效性。
- 安全性通过自控病例系列分析评估,比较任何重组带状疱疹疫苗接种后30天内经病历确认的类风湿关节炎 flare 与对照期,采用条件Poisson回归估计相对风险。
主要发现
- 在50岁及以上类风湿关节炎成人中(2剂接种者1926例;未接种者5746例),2剂重组带状疱疹疫苗对带状疱疹的调整疫苗有效性为60.7%(95%CI 41.0%-73.8%)。
- 在2剂间隔4周至6个月接种者的亚组分析中,对带状疱疹的疫苗有效性为57.9%(95%CI 34.4%-73.0%)。
- 2剂重组带状疱疹疫苗对带状疱疹后神经痛的调整疫苗有效性为88.7%(95%CI 12.1%-98.5%)。
- 在2606例接种至少1剂重组带状疱疹疫苗的类风湿关节炎成人中,未观察到接种后30天内类风湿关节炎 flare 风险增加(RR 1.02;95%CI 0.75-1.37)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In an interim analysis, we evaluated vaccine effectiveness (VE) against herpes zoster (HZ) and postherpetic neuralgia (PHN) and safety of recombinant zoster vaccine (RZV) in adults aged ≥50 years with rheumatoid arthritis (RA). METHODS: VE was assessed using a retrospective matched cohort analysis of Kaiser Permanente Southern California members aged ≥50 years with RA receiving 2 RZV doses (≥4 weeks apart) and matched up to 1:3 to RZV-unvaccinated individuals. Stratified Cox proportional hazards regression was used to estimate adjusted hazard ratios and VE against HZ and PHN. Safety was assessed using a self-controlled case series analysis of chart-confirmed RA flare within 30 days after any RZV vaccination versus comparison periods. The relative risk (RR) was estimated using conditional Poisson regression. RESULTS: In adults ≥50 years with RA (2-dose vaccinated: 1926; unvaccinated: 5746), the adjusted VE of 2 RZV doses against HZ was 60.7% (95% CI, 41.0%-73.8%); in a subgroup analysis among those who received 2 doses 4 weeks to 6 months apart, VE against HZ was 57.9% (95% CI, 34.4%-73.0%). Adjusted VE of 2 RZV doses against PHN was 88.7% (95% CI, 12.1%-98.5%). Among 2606 adults with RA who received ≥1 RZV dose, no increased risk of RA flares within 30 days after RZV vaccination was observed (RR, 1.02; 95% CI, 0.75-1.37). CONCLUSIONS: Among adults ≥50 years with RA, 2 RZV doses provided protection against HZ and PHN. The study did not observe an increased risk of RA flares within 30 days following RZV vaccination.
引用
- Rayens E, Sy LS, Qian L, et al. Effectiveness and safety of the recombinant zoster vaccine in individuals ≥50 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study. Ann Rheum Dis. 2025. PMID: 39979209. doi:10.1016/j.ard.2025.01.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。